Search

Brian J Davis

Examiner (ID: 17895, Phone: (571)272-0638 , Office: P/1672 )

Most Active Art Unit
1621
Art Unit(s)
1615, 1672, 1614, 1621, 1627, 1612
Total Applications
2844
Issued Applications
2304
Pending Applications
200
Abandoned Applications
369

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 20192170 [patent_doc_number] => 20250268880 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-08-28 [patent_title] => 3-(Hydroxy)-Pyridin-4(1H)-One Compounds and Methods of Making and Using the Same [patent_app_type] => utility [patent_app_number] => 19/202501 [patent_app_country] => US [patent_app_date] => 2025-05-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14069 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19202501 [rel_patent_id] =>[rel_patent_doc_number] =>)
19/202501
3-(Hydroxy)-Pyridin-4(1H)-One Compounds and Methods of Making and Using the Same May 7, 2025 Pending
18/852937 CATIONIC LIPID COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF Apr 21, 2025 Pending
Array ( [id] => 19816655 [patent_doc_number] => 20250074862 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-03-06 [patent_title] => CRYSTALLINE FORM OF TRIETHYLENETETRAMINE TETRAHYDROCHLORIDE AND ITS PHARMACEUTICAL USE [patent_app_type] => utility [patent_app_number] => 18/948050 [patent_app_country] => US [patent_app_date] => 2024-11-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11630 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 102 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18948050 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/948050
Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use Nov 13, 2024 Issued
Array ( [id] => 19792238 [patent_doc_number] => 12233161 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2025-02-25 [patent_title] => Lipids and lipid nanoparticle formulations [patent_app_type] => utility [patent_app_number] => 18/669214 [patent_app_country] => US [patent_app_date] => 2024-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43405 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 136 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18669214 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/669214
Lipids and lipid nanoparticle formulations May 19, 2024 Issued
Array ( [id] => 19884095 [patent_doc_number] => 12269787 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2025-04-08 [patent_title] => Method to selectively produce benzalaniline from a Schiff-base reaction involving aniline and benzaldehyde [patent_app_type] => utility [patent_app_number] => 18/668526 [patent_app_country] => US [patent_app_date] => 2024-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 3534 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18668526 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/668526
Method to selectively produce benzalaniline from a Schiff-base reaction involving aniline and benzaldehyde May 19, 2024 Issued
Array ( [id] => 19642857 [patent_doc_number] => 20240417377 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-19 [patent_title] => COMPOUNDS, COMPOSITIONS, AND METHODS FOR SELECTIVELY INHIBITING ss-GLUCURONIDASES AND ALLEVIATING SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT INDUCED DIARRHEA [patent_app_type] => utility [patent_app_number] => 18/659997 [patent_app_country] => US [patent_app_date] => 2024-05-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27296 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18659997 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/659997
COMPOUNDS, COMPOSITIONS, AND METHODS FOR SELECTIVELY INHIBITING ss-GLUCURONIDASES AND ALLEVIATING SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT INDUCED DIARRHEA May 8, 2024 Abandoned
Array ( [id] => 19921666 [patent_doc_number] => 12295925 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-05-13 [patent_title] => Treatment of neurofibromatosis type 1 (NF1) associated plexiform neurofibromas (PN) in pediatric patients with mirdametinib [patent_app_type] => utility [patent_app_number] => 18/648426 [patent_app_country] => US [patent_app_date] => 2024-04-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6683 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18648426 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/648426
Treatment of neurofibromatosis type 1 (NF1) associated plexiform neurofibromas (PN) in pediatric patients with mirdametinib Apr 27, 2024 Issued
Array ( [id] => 19938849 [patent_doc_number] => 12310962 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-05-27 [patent_title] => Methods and compositions for treating cancer [patent_app_type] => utility [patent_app_number] => 18/647511 [patent_app_country] => US [patent_app_date] => 2024-04-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 7 [patent_no_of_words] => 2350 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 102 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18647511 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/647511
Methods and compositions for treating cancer Apr 25, 2024 Issued
Array ( [id] => 19860659 [patent_doc_number] => 20250099445 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-03-27 [patent_title] => METHODS OF TREATMENT OF TUBEROUS SCLEROSIS COMPLEX [patent_app_type] => utility [patent_app_number] => 18/641640 [patent_app_country] => US [patent_app_date] => 2024-04-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12419 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18641640 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/641640
METHODS OF TREATMENT OF TUBEROUS SCLEROSIS COMPLEX Apr 21, 2024 Pending
Array ( [id] => 19948335 [patent_doc_number] => 12319682 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-06-03 [patent_title] => Indole and benzimidazole derivatives as dual 5-HT [patent_app_type] => utility [patent_app_number] => 18/637083 [patent_app_country] => US [patent_app_date] => 2024-04-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15489 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18637083 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/637083
Indole and benzimidazole derivatives as dual 5-HT Apr 15, 2024 Issued
Array ( [id] => 19448909 [patent_doc_number] => 20240309039 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-19 [patent_title] => PHOSPHORAMIDATES FOR THE TREATMENT OF HEPATITIS B VIRUS [patent_app_type] => utility [patent_app_number] => 18/632908 [patent_app_country] => US [patent_app_date] => 2024-04-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17307 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18632908 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/632908
PHOSPHORAMIDATES FOR THE TREATMENT OF HEPATITIS B VIRUS Apr 10, 2024 Pending
Array ( [id] => 19554771 [patent_doc_number] => 20240366563 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-07 [patent_title] => METHODS OF TREATING MALIGNANT LYMPHOPROLIFERATIVE DISORDERS [patent_app_type] => utility [patent_app_number] => 18/630283 [patent_app_country] => US [patent_app_date] => 2024-04-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13406 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 82 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18630283 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/630283
METHODS OF TREATING MALIGNANT LYMPHOPROLIFERATIVE DISORDERS Apr 8, 2024 Abandoned
Array ( [id] => 19331218 [patent_doc_number] => 20240245648 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-25 [patent_title] => TREATMENTS WITH NIROGACESTAT [patent_app_type] => utility [patent_app_number] => 18/624670 [patent_app_country] => US [patent_app_date] => 2024-04-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28383 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18624670 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/624670
Treatments with nirogacestat Apr 1, 2024 Issued
Array ( [id] => 19379219 [patent_doc_number] => 20240269089 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-15 [patent_title] => MYRCENE-CONTAINING COMPLEX MIXTURES TARGETING TRPV1 [patent_app_type] => utility [patent_app_number] => 18/624108 [patent_app_country] => US [patent_app_date] => 2024-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15241 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 89 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18624108 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/624108
MYRCENE-CONTAINING COMPLEX MIXTURES TARGETING TRPV1 Mar 31, 2024 Pending
Array ( [id] => 19299878 [patent_doc_number] => 20240228447 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-11 [patent_title] => SUBSTITUTED NAPHTHYL P38ALPHA MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS [patent_app_type] => utility [patent_app_number] => 18/618110 [patent_app_country] => US [patent_app_date] => 2024-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20120 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 108 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18618110 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/618110
Substituted naphthyl P38alpha mitogen-activated protein kinase inhibitors Mar 26, 2024 Issued
Array ( [id] => 19379204 [patent_doc_number] => 20240269074 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-15 [patent_title] => LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 18/617058 [patent_app_country] => US [patent_app_date] => 2024-03-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 59955 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -63 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18617058 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/617058
LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS Mar 25, 2024 Pending
Array ( [id] => 19682262 [patent_doc_number] => 20250000807 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-02 [patent_title] => circCDK13-ENRICHED ENGINEERED SMALL EXTRACELLULAR VESICLE (E-sEV), AND PREPARATION METHOD AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/613014 [patent_app_country] => US [patent_app_date] => 2024-03-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4204 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18613014 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/613014
circCDK13-ENRICHED ENGINEERED SMALL EXTRACELLULAR VESICLE (E-sEV), AND PREPARATION METHOD AND USE THEREOF Mar 20, 2024 Pending
Array ( [id] => 19248640 [patent_doc_number] => 20240199627 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-20 [patent_title] => MONOHYDRATE AND CRYSTALLINE FORMS OF 6-[(3S,4S)-4-METHYL-1-(PYRIMIDIN-2-YLMETHYL)PYRROLIDIN-3-YL]-3-TETRAHYDROPYRAN-4-YL-7H-IMIDAZO[1,5-A]PYRAZIN-8-ONE [patent_app_type] => utility [patent_app_number] => 18/594898 [patent_app_country] => US [patent_app_date] => 2024-03-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16425 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 7 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18594898 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/594898
Monohydrate and crystalline forms of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one Mar 3, 2024 Issued
Array ( [id] => 19417197 [patent_doc_number] => 20240293320 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-05 [patent_title] => Mechanism for Bioavailable Delivery of Electrolytes [patent_app_type] => utility [patent_app_number] => 18/593290 [patent_app_country] => US [patent_app_date] => 2024-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6869 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 235 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18593290 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/593290
Mechanism for Bioavailable Delivery of Electrolytes Feb 29, 2024 Pending
Array ( [id] => 19543072 [patent_doc_number] => 20240360108 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-31 [patent_title] => SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 18/581307 [patent_app_country] => US [patent_app_date] => 2024-02-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 116521 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18581307 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/581307
SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE Feb 18, 2024 Pending
Menu